AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17389731
Drug: Low-dose digoxin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose digoxin (≤ 0.125 mg/d)
Trial: 7857343
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of pidotimod (200 mg in bolus)
Trial: 7857343
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of pidotimod at 200, 400, and 800 mg
Trial: 7857343
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of pidotimod at 50, 100, and 200 mg (12 volunteers/group) twice a day for 15 days
Trial: 7857343
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of pidotimod (800 mg) in different formulations (sachets, vials, tablets)
Trial: 2575335
Drug: Zinc gluconate
RxNorm normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc gluconate (200 mg/day, corresponding to 30 mg zinc metal)
Trial: 23400965
Drug: H₂-water (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H₂-water (1,000 mL/day for 48 weeks)
Trial: 8640816
Drug: Antioxidant supplementation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplementation (vitamin C 100 mg/day, vitamin E 280 mg/day, beta-carotene 25 mg/day) for 20 weeks
Trial: 6752720
Drug: Alkylating agents
RxNorm normalized name: ALKYLATING AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alkylating agents (melphalan and chlorambucil)
Trial: 6752720
Drug: Surgery or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery or radiation or both without alkylating agents
Trial: 6752720
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (alkylating agents)
Trial: 30669181
Drug: i.v. fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. fluid administration
Trial: 30372711
Drug: Desoximetasone spray
RxNorm normalized name: desoximetasone Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desoximetasone spray 0.25% with twice-daily telephone calls to discuss treatment adherence
Trial: 30372711
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment adherence support (control group)
Trial: 26827913
Drug: PSX1002-GB 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSX1002-GB 12.5 μg
Trial: 26827913
Drug: PSX1002-GB 25
RxNorm normalized name: GB-13
DrugBank: GB-13 (DB18387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSX1002-GB 25 μg
Trial: 26827913
Drug: PSX1002-GB 50
RxNorm normalized name: GB-13
DrugBank: GB-13 (DB18387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSX1002-GB 50 μg
Trial: 26827913
Drug: PSX1002-GB 100
RxNorm normalized name: GB-13
DrugBank: GB-13 (DB18387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSX1002-GB 100 μg
Trial: 24500245
Drug: SAMe 1,600‐3,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAMe 1,600‐3,200 mg/d
Trial: 19683590
Drug: Aclidinium (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aclidinium (all doses)
Trial: 15716198
Drug: Alfuzosin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin (5 mg twice daily)
Trial: 15716198
Drug: Tamsulosin (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (0.4 mg once daily)
Trial: 7626351
Drug: Warfarin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin treatment (group 2)
Trial: 7626351
Drug: No antithrombotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antithrombotic medication (group 1)
Trial: 7626351
Drug: Aspirin treatment
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin treatment (group 3)
Trial: 20394251
Drug: PCA remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA remifentanil 0.5 microg/kg as a loading bolus, 0.25 microg/kg PCA bolus, continuous infusion of 0.05 microg/kg/min
Trial: 12147804
Drug: Fluvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin (20 mg/day p.o.)
Trial: 7619749
Drug: Cisplatin (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (120 mg/sqm day 1) + etoposide (100 mg/sqm days 1-3) every 3 weeks (PE)
Trial: 7619749
Drug: Cisplatin (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (120 mg/sqm every 4 weeks) + mitomycin-C (8 mg/sqm days 1-29-71) + vindesine (3 mg/sqm days 1-8-15-22) (MVP)
Trial: 7619749
Drug: Cisplatin (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (120 mg/sqm day 1) + mitomycin-C (6 mg/sqm day 1) + ifosfamide (3 mg/sqm day 2) every 3 weeks (MIC)
Trial: 2797631
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of aspirin per day
Trial: 2797631
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of aspirin per day
Trial: 2797631
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg of aspirin per day
Trial: 31729443
Drug: Biophysical propensity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biophysical propensity scales as input features for ML methods
Trial: 31729443
Drug: Non-linear ML
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-linear ML methods
Trial: 29076670
Drug: Nigella sativa
RxNorm normalized name: NIGELLA SATIVA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nigella sativa 1g twice a day for 12 weeks
Trial: 26063318
Drug: Standard Western
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Western Medicine Treatment (SWMT)
Trial: 23952636
Drug: Tirasemtiv (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirasemtiv (375 mg daily for two weeks, with and without riluzole; 500 mg daily in two divided doses for three weeks)
Trial: 17089219
Drug: Thermal mineral
RxNorm normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermal mineral water treatment
Trial: 19197573
Drug: Tap water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tap water treatment (Control)
Trial: 15505457
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine infusion (90 seconds)
Trial: 15505457
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion (90 seconds)
Trial: 11678162
Drug: Timolol GS
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol GS (TIMOPTIC‐XE), 0.5% once daily
Trial: 11678162
Drug: Timolol maleate
RxNorm normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol maleate ophthalmic solution, 0.5% twice daily
Trial: 26853333
Drug: Surgical staging
RxNorm normalized name: fluorexon stain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical staging followed by chemoradiation therapy (CRT) (arm A)
Trial: 26853333
Drug: Clinical staging
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical staging followed by chemoradiation therapy (CRT) (arm B)
Trial: 26178889
Drug: Zoledronate (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoledronate (5 mg intravenously per year for two years)
Trial: 16731539
Drug: TAM‐LHRHa (LHRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAM‐LHRHa (LHRH agonist plus tamoxifen)
Trial: 8143951
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g of alcohol
Trial: 3548626
Drug: Oral ketoconazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ketoconazole, 400 mg/d
Trial: 31549147
Drug: 12-month treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-month treatment regimen containing clofazimine (CFZ)
Trial: 31549147
Drug: 18-month treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 18-month treatment regimen (control group)
Trial: 21171261
Drug: Tamsulosin 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.2 mg qd
Trial: 21171261
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tamsulosin and tolterodine 2 mg bid
Trial: 10499246
Drug: Postmastectomy locoregional
RxNorm normalized name: GELATIN,ABSORBABLE PROSTATECTOMY CONE,SZ 13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postmastectomy locoregional radiation therapy
Trial: 7798683
Drug: Active postexposure
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active postexposure prophylaxis with two different vaccines
Trial: 7798683
Drug: Passive-active immunoprophylaxis
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive-active immunoprophylaxis with high-dose hepatitis B immune globulin
Trial: 30959314
Drug: Clarithromycin treatment
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin treatment (14-day duration)
Trial: 27730425
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab (IVR) injections and short pulse focal/grid laser photocoagulation
Trial: 26176347
Drug: Atropine (pre-treatment)
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine (pre-treatment)
Trial: 26176347
Drug: Ondansetron (pre-treatment)
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron (pre-treatment)
Trial: 22762238
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of neuromuscular electrical stimulation (NMES) and balloon dilatation for 4 months
Trial: 22762238
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of NMES and balloon dilatation
Trial: 19634161
Drug: Weekly carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weekly carboplatin (AUC 1.5) and paclitaxel (45 mg/m2) with daily subcutaneous amifostine (500 mg)
Trial: 19634161
Drug: Weekly carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weekly carboplatin (AUC 1.5) and paclitaxel (45 mg/m2) without amifostine
Trial: 19634161
Drug: Weekly carboplatin/paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly carboplatin/paclitaxel with concomitant boost radiation
Trial: 19634161
Drug: Weekly carboplatin/paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly carboplatin/paclitaxel with daily subcutaneous amifostine
Trial: 17526165
Drug: Spleen-invigorating Prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spleen-invigorating Prescription (SIP), orally, twice a day for 6 months
Trial: 17526165
Drug: Control group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group: intramuscular injection with human interferon alpha 1b, 3 times a week
Trial: 15063521
Drug: Low-intensity pulsed
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity pulsed ultrasound (LIPUS) for delayed union treatment
Trial: 7908268
Drug: Inhaled corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroid (budesonide) plus beta 2-agonist (salbutamol) 0.2 mg, t.i.d.
Trial: 7908268
Drug: Beta 2-agonist
RxNorm normalized name: 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN
DrugBank: Hydroxypropyl betadex (DB15379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta 2-agonist (salbutamol) alone
Trial: 3465425
Drug: Vigabatrin (gamma-vinyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigabatrin (gamma-vinyl GABA) at a daily dose of 2-4 g for 4 months
Trial: 3465425
Drug: Vigabatrin (gamma-vinyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigabatrin (gamma-vinyl GABA) at a daily dose of 2 g/day for 3 months
Trial: 3465425
Drug: Vigabatrin (gamma-vinyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigabatrin (gamma-vinyl GABA) at a daily dose of 4 g/day
Trial: 3465425
Drug: Vigabatrin (gamma-vinyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigabatrin (gamma-vinyl GABA) at a daily dose of 2 g/day
Trial: 30567490
Drug: Hydromorphone (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone (0.2 mg/kg) + dezocine (0.5 mg/kg) + ramosetron (0.6 mg) diluted with normal saline to 200 mL
Trial: 30567490
Drug: Sufentanil (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil (3.0 μg/kg) + dezocine (0.5 mg/kg) + ramosetron (0.6 mg) diluted with normal saline to 200 mL
Trial: 26551550
Drug: Ramosetron 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramosetron 2.5 μg once daily for 12 weeks
Trial: 18626707
Drug: Controlled-release oxycodone
RxNorm normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Controlled-release oxycodone administered 1 hour before surgery and 12 hours after the first administration
Trial: 10492054
Drug: Controlled-release oxycodone
RxNorm normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Controlled-release oxycodone
Trial: 18626707
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered at the same intervals as oxycodone
Trial: 15447698
Drug: Rizatriptan 5
RxNorm normalized name: rizatriptan 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rizatriptan 5 mg (tablets)
Trial: 15447698
Drug: Rizatriptan 5
RxNorm normalized name: rizatriptan 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rizatriptan 5 mg (wafers)
Trial: 11228217
Drug: 3.75 mg
RxNorm normalized name: zopiclone 3.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 mg triptorelin (conventional dose)
Trial: 11228217
Drug: 1.87 mg
RxNorm normalized name: proline 1.87 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.87 mg triptorelin (low dose)
Trial: 11228217
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of triptorelin
Trial: 3535002
Drug: Placebo/metoprolol 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo/metoprolol 10 mg i.v. in patients with normal UAE
Trial: 3535002
Drug: Placebo/metoprolol 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo/metoprolol 10 mg i.v. in patients with incipient nephropathy
Trial: 3535002
Drug: Metoprolol 200
RxNorm normalized name: metoprolol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 200 mg/24 h and hydroflumethiazid 25 mg/24 h during long-term treatment
Trial: 16399110
Drug: Gabexate mesilate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabexate mesilate (GM) administered intravenously at a dosage of 2.0 mg/kg/h starting 12 hours before surgery until postoperative day 2
Trial: 15276504
Drug: Bradykinin infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bradykinin infusion (25 microg for 7 minutes)
Trial: 15276504
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no bradykinin infusion)
Trial: 11422001
Drug: Moclobemide (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (150 mg tablet every 12 h for 8 days) + Almotriptan (12.5 mg tablet on day 8)
Trial: 11422001
Drug: Almotriptan (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almotriptan (12.5 mg tablet on day 8)
Trial: 9266290
Drug: Nisoldipine coat-core
RxNorm normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nisoldipine coat-core formulation
Trial: 9266290
Drug: Intravenous formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous formulation
Trial: 7905660
Drug: Ebrotidine (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebrotidine (800 mg) plus ASA (500 mg)
Trial: 7905660
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus ASA (500 mg)
Trial: 3641787
Drug: Fosfomycin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosfomycin plus ampicillin (4 g fosfomycin every 8 h and 1 g ampicillin every 6 h)
Trial: 3641787
Drug: Gentamicin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin plus ampicillin (80 mg gentamicin every 8 h and 1 g ampicillin every 6 h)
Trial: 31880993
Drug: 0.2 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 g/kg BW oyster meat preload
Trial: 31880993
Drug: 0.1 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 g/kg BW oyster meat preload
Trial: 31880993
Drug: 0 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g/kg BW (control)
Trial: 9607383
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg irbesartan
Trial: 9512880
Drug: Enrolled in
RxNorm normalized name: Enromed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled in vaccine trial
Trial: 9512880
Drug: Not enrolled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not enrolled in vaccine trial
Trial: 623136
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (hydrochlorothiazide + alpha methyldopa)
Trial: 22231150
Drug: Intravenous fluids
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fluids
Trial: 20884007
Drug: Rosuvastatin (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (5, 10, or 20 mg) for a mean period of 29 weeks
Trial: 19349630
Drug: Triple-combination pharmacotherapy
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-combination pharmacotherapy (nicotine patch, nicotine oral inhaler, and bupropion ad libitum)
Trial: 19349630
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch alone for a standard 10-week course
Trial: 19349630
Drug: Triple-combination pharmacotherapy
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-combination pharmacotherapy
Trial: 17873238
Drug: Rivaroxaban 30
RxNorm normalized name: rivaroxaban 30-Day Starter Pack (42-15 MG Oral Tablets & 9-20 MG Oral Tablets)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 30 mg
Trial: 14985222
Drug: Zinc alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc alone (10 mg Zn; n = 81)
Trial: 11371689
Drug: Abacavir (ABC)
DrugBank: Abacavir (DB01048)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abacavir (ABC) 600 mg twice daily
Trial: 2647807
Drug: Analgesic imagery
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic imagery
Trial: 30269035
Drug: Cranberry diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry diet (animal-based diet plus 30 g/day freeze-dried whole cranberry powder)
Trial: 30269035
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet (animal-based diet plus 30 g/day placebo powder)
Trial: 26434651
Drug: Adjunctive full-mouth
RxNorm normalized name: moth bean extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive full-mouth intensive removal of subgingival dental plaque biofilms with scaling and root planning (group 2)
Trial: 25082595
Drug: Granisetron (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron (40 μg/kg)
Trial: 20362507
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (4 mg intravenously every 3 weeks for 1 year)
Trial: 17327378
Drug: PPARgamma agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPARgamma agonist (rosiglitazone)
Trial: 17327378
Drug: PPARalpha agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPARalpha agonist (fenofibrate)
Trial: 17327378
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of metyrapone and RU38486 (glucocorticoid blockade)
Trial: 12395217
Drug: Water dispersible
RxNorm normalized name: GNP Vitamin E 400units Water Dispersible Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water dispersible beta-carotene powder (7.2 mg/d)
Trial: 12395217
Drug: Water dispersible
RxNorm normalized name: GNP Vitamin E 400units Water Dispersible Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water dispersible beta-carotene powder (21.6 mg/d)
Trial: 12395217
Drug: Carrot juice-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carrot juice-based drink (6 mg/d)